Peptide-Based Vaccination for Antibody Responses Against HIV
HIV-1 is responsible for a global pandemic of 35 million people and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, whereas a th...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/7/3/105 |
| _version_ | 1811263445556789248 |
|---|---|
| author | Behazine Combadière Manon Beaujean Chloé Chaudesaigues Vincent Vieillard |
| author_facet | Behazine Combadière Manon Beaujean Chloé Chaudesaigues Vincent Vieillard |
| author_sort | Behazine Combadière |
| collection | DOAJ |
| description | HIV-1 is responsible for a global pandemic of 35 million people and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, whereas a therapeutic vaccine might help to mitigate the clinical course of the disease and to contribute to virus eradication strategies. However, despite more than 30 years of research, we do not have a vaccine capable of protecting against HIV-1 infection or impacting on disease progression. This, in part, denotes the challenge of identifying immunogens and vaccine modalities with a reduced risk of failure in late stage development. However, progress has been made in epitope identification for the induction of broadly neutralizing antibodies. Thus, peptide-based vaccination has become one of the challenges of this decade. While some researchers reconstitute envelope protein conformation and stabilization to conserve the epitope targeted by neutralizing antibodies, others have developed strategies based on peptide-carrier vaccines with a similar goal. Here, we will review the major peptide-carrier based approaches in the vaccine field and their application and recent development in the HIV-1 field. |
| first_indexed | 2024-04-12T19:45:32Z |
| format | Article |
| id | doaj.art-78f5cb7f409346b9b4f7b4e722918fe0 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-04-12T19:45:32Z |
| publishDate | 2019-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-78f5cb7f409346b9b4f7b4e722918fe02022-12-22T03:18:58ZengMDPI AGVaccines2076-393X2019-09-017310510.3390/vaccines7030105vaccines7030105Peptide-Based Vaccination for Antibody Responses Against HIVBehazine Combadière0Manon Beaujean1Chloé Chaudesaigues2Vincent Vieillard3Sorbonne University, UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Center of Immunology and Infectious Diseases (CIMI-Paris), 91 Boulevard de l’Hôpital, F-75013 Paris, FranceSorbonne University, UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Center of Immunology and Infectious Diseases (CIMI-Paris), 91 Boulevard de l’Hôpital, F-75013 Paris, FranceSorbonne University, UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Center of Immunology and Infectious Diseases (CIMI-Paris), 91 Boulevard de l’Hôpital, F-75013 Paris, FranceSorbonne University, UPMC Univ Paris 06, INSERM, U1135, CNRS, ERL 8255, Center of Immunology and Infectious Diseases (CIMI-Paris), 91 Boulevard de l’Hôpital, F-75013 Paris, FranceHIV-1 is responsible for a global pandemic of 35 million people and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, whereas a therapeutic vaccine might help to mitigate the clinical course of the disease and to contribute to virus eradication strategies. However, despite more than 30 years of research, we do not have a vaccine capable of protecting against HIV-1 infection or impacting on disease progression. This, in part, denotes the challenge of identifying immunogens and vaccine modalities with a reduced risk of failure in late stage development. However, progress has been made in epitope identification for the induction of broadly neutralizing antibodies. Thus, peptide-based vaccination has become one of the challenges of this decade. While some researchers reconstitute envelope protein conformation and stabilization to conserve the epitope targeted by neutralizing antibodies, others have developed strategies based on peptide-carrier vaccines with a similar goal. Here, we will review the major peptide-carrier based approaches in the vaccine field and their application and recent development in the HIV-1 field.https://www.mdpi.com/2076-393X/7/3/105peptide-conjugateHIV-1neutralizing antibodiesvaccinationadjuvants |
| spellingShingle | Behazine Combadière Manon Beaujean Chloé Chaudesaigues Vincent Vieillard Peptide-Based Vaccination for Antibody Responses Against HIV Vaccines peptide-conjugate HIV-1 neutralizing antibodies vaccination adjuvants |
| title | Peptide-Based Vaccination for Antibody Responses Against HIV |
| title_full | Peptide-Based Vaccination for Antibody Responses Against HIV |
| title_fullStr | Peptide-Based Vaccination for Antibody Responses Against HIV |
| title_full_unstemmed | Peptide-Based Vaccination for Antibody Responses Against HIV |
| title_short | Peptide-Based Vaccination for Antibody Responses Against HIV |
| title_sort | peptide based vaccination for antibody responses against hiv |
| topic | peptide-conjugate HIV-1 neutralizing antibodies vaccination adjuvants |
| url | https://www.mdpi.com/2076-393X/7/3/105 |
| work_keys_str_mv | AT behazinecombadiere peptidebasedvaccinationforantibodyresponsesagainsthiv AT manonbeaujean peptidebasedvaccinationforantibodyresponsesagainsthiv AT chloechaudesaigues peptidebasedvaccinationforantibodyresponsesagainsthiv AT vincentvieillard peptidebasedvaccinationforantibodyresponsesagainsthiv |